AI-generated analysis. Always verify with the original filing.
DexCom, Inc. reported Q4 2025 revenue of $1.260 billion, up 13% year-over-year, GAAP operating income of $323.0 million (25.6% of revenue), and full-year 2025 revenue of $4.662 billion, up 16%. The company reiterated 2026 revenue guidance of $5.16-$5.25 billion and highlighted launches of Dexcom G7 15 Day CGM and Dexcom Smart Basal.
Event Type
Disclosure
Mandatory
Variant
8-K
, including Exhibit 99.1 hereto, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the
. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 99.1 Press release dated February 12, 2026 104 Cover Page Interactive Data File (formatted
| Metric | Value | Basis |
|---|---|---|
| Revenue | $1.26 | |
| Gross Profit | $792.70 | GAAP |
| Gross Margin | 62.9% | GAAP |
| Operating Income | $323.00 | GAAP |
| Operating Margin | 25.6% | GAAP |
| Net Income | $267.30 | GAAP |
| Diluted Net Income Per Share | $0.68 | GAAP |